CDMO News
Amaran Biotech Signs MOU with Nippon Fine Chemical for Nanoparticle Drug CDMO Expansion
Amaran Biotechnology Inc., a subsidiary of OBI Pharma specializing in CDMO services, has signed a Memorandum of Understanding (MOU) with Japan-based Nippon Fine Chemical Co., Ltd. and its Taiwan subsidiary, Zillion Fine Chemicals International Co., Ltd. The collaboration aims to advance nanoparticle-based drug contract
7 March 2025
Stay ahead of trends and best practices
